Ireland - English - HPRA (Health Products Regulatory Authority)

le vet bv - enrofloxacin - tablet - 150 mg/tablet - enrofloxacin - dogs - antibacterial

Ireland - English - HPRA (Health Products Regulatory Authority)

le vet bv - enrofloxacin - tablet - 50 mg/tablet - enrofloxacin - dogs - antibacterial

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - enrofloxacin - oral tablet - enrofloxacin antibiotic active 150.0 mg/tb - antibiotic & related - dog - older than 12 months - antibiotics - oral, parenteral | infections of the respiratory tract | infections of the urinary tracts | staphylococcus intermedius | wound infections | abscesses | acute respiratory infections | airsacculitis | amoxycillin sensitive bacteria | anaerobic bacterial infection | avian mycoplasmas | bronchiseptica | bronchitis | clavulanic acid sensitive | coccidiosis | coryza | crd | deep pyodermas | dermatoses | diarrhoea | endometritis | enteritis | enzootic pneumonia | escherichia coli | european brood disease | gentamicin sensitive | group d streptococcus | hypermotility | including secondary invaders | infected wounds | infections | klebsiella spp. | lactating | mastitis | pharyngitis | pneumonia | proteus spp. | protozoal infections | pseudomonas aeruginosa | pyometra | salmonellosis | seborrhoeic dermatitis | sinusitis | staphylococcus spp. | systemic bacterial infection | tonsillitis

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - enrofloxacin - oral tablet - enrofloxacin antibiotic active 50.0 mg/tb - antibiotic & related - cat - over 12 weeks old | dog - older than 12 months - antibiotics - oral, parenteral | infections of the respiratory tract | infections of the urinary tracts | osteomyelitis | septicemia | staphylococcus intermedius | wound infections | abscesses | acute respiratory infections | airsacculitis | amoxycillin sensitive bacteria | anaerobic bacterial infection | avian mycoplasmas | bronchiseptica | bronchitis | clavulanic acid sensitive | coccidiosis | coryza | crd | deep pyodermas | dermatoses | diarrhoea | endometritis | enteritis | enzootic pneumonia | escherichia coli | european brood disease | gentamicin sensitive | gram negative septicaemias | group d streptococcus | hypermotility | including secondary invaders | infected wounds | infections | klebsiella spp. | lactating | mastitis | pharyngitis | pneumonia | proteus spp. | protozoal infections | pseudomonas aeruginosa | pyometra | salmonellosis | seborrhoeic dermatitis | sinusitis | staphylococcus spp. | systemic bacterial infection | tonsillitis | viremia

Ireland - English - HPRA (Health Products Regulatory Authority)

bayer limited - enrofloxacin - tablets - 150 mg/tablet - enrofloxacin - canine - antibacterial

Ireland - English - HPRA (Health Products Regulatory Authority)

bayer limited - enrofloxacin - tablets - 50 mg/tablet - enrofloxacin - canine - antibacterial

Ireland - English - HPRA (Health Products Regulatory Authority)

bayer limited - enrofloxacin - tablet - 150 mg/tablet - enrofloxacin - dogs - antibacterial

Ireland - English - HPRA (Health Products Regulatory Authority)

bayer limited - enrofloxacin - tablet - 50 mg/tablet - enrofloxacin - dogs - antibacterial

United States - English - NLM (National Library of Medicine)

mwi/vetone - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin flavored tablets are indicated for the management of diseases associated with bacteria susceptible to enrofloxacin. enrofloxacin flavored tablets are indicated for use in dogs and cats. enrofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones. dogs: based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or giant breeds.

United States - English - NLM (National Library of Medicine)

aspen veterinary resources®, ltd - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin flavored tablets are indicated for the management of diseases associated with bacteria susceptible to enrofloxacin. enrofloxacin flavored tablets are indicated for use in dogs and cats. enrofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones. dogs: based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or giant breeds.